PubRank

André Pèlegrin

Author PubWeight™ 32.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008 1.54
2 Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J Nucl Med 2010 1.45
3 In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007 1.35
4 Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res 2008 1.30
5 Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010 1.12
6 Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol 2011 1.10
7 Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem 2011 1.08
8 Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res 2008 1.00
9 In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption. Neoplasia 2012 0.98
10 Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 2005 0.98
11 MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin Cancer Res 2005 0.97
12 Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia 2013 0.93
13 R-Cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase. Cancer Res 2008 0.92
14 Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J 2009 0.92
15 Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med 2009 0.91
16 General overview of radioimmunotherapy of solid tumors. Immunotherapy 2013 0.89
17 Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther 2013 0.87
18 Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One 2013 0.87
19 Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol 2013 0.84
20 Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer. PLoS One 2012 0.83
21 The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J 2004 0.82
22 Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer. Clin Cancer Res 2008 0.81
23 Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen. Tumour Biol 2003 0.80
24 A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. Vaccine 2009 0.80
25 Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer 2004 0.80
26 Pharmacokinetic and tumor-seeking properties of recombinant and nonrecombinant anti-carcinoembryonic antigen antibody fragments. Int J Cancer 2002 0.78
27 The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4. MAbs 2014 0.78
28 High level prokaryotic expression of anti-Müllerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging. J Immunol Methods 2012 0.77
29 Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein. Protein Eng Des Sel 2008 0.77
30 Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody. Int J Radiat Oncol Biol Phys 2003 0.76
31 A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis. Angew Chem Int Ed Engl 2005 0.76
32 The lipid-modulating effects of a CD4-specific recombinant antibody correlate with ZAP-70 segregation outside membrane rafts. Immunol Lett 2010 0.76
33 [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials]. Bull Cancer 2003 0.75
34 Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers. Front Oncol 2013 0.75
35 Cyclization of peptides through a urea bond: application to the Arg-Gly-Asp tripeptide. Chembiochem 2010 0.75
36 [Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment]. Bull Cancer 2007 0.75
37 [Combined anti-EGFR and anti-HER2 monoclonal antibodies: preclinical efficacy in the treatment of pancreatic cancer]. Med Sci (Paris) 2007 0.75
38 CD4 ligation excludes the Carma1-Bcl10-MALT1 complex from GM1-positive membrane rafts in CD3/CD28 activated T cells. Cell Immunol 2011 0.75